BridgeBio Pharma (BBIO)
Market Price (8/13/2026): $84.99 | Market Cap: $16.6 BilSector: Health Care | Industry: Biotechnology
BridgeBio Pharma (BBIO)
Market Price (8/13/2026): $84.99Market Cap: $16.6 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 202% Low stock price volatilityVol 12M is 48% Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.5, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -478 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -67% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 21% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -61%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -61% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.6% Key risksBBIO key risks include [1] substantial doubt about its ability to continue as a going concern due to recurring losses and high debt, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 202% |
| Low stock price volatilityVol 12M is 48% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.5, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -478 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -67% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 21% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -61%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -61% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.6% |
| Key risksBBIO key risks include [1] substantial doubt about its ability to continue as a going concern due to recurring losses and high debt, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 8/10/2026
BridgeBio Pharma (BBIO) stock has gained about 20% since 4/30/2026 because of the following key factors:
1. Robust Commercial Performance of Attruby (acoramidis) Driven by Strong Revenue Growth and Differentiated Clinical Data. BridgeBio Pharma's flagship product, Attruby, demonstrated significant commercial success in fiscal Q2 2026 (ended June 30, 2026), with net product revenue reaching $222.4 million. This represents a substantial increase of $150.9 million year over year and more than $35 million sequentially. Management noted Attruby's 23% growth rate, outperforming the broader market's 19% increase. The commercial momentum was further bolstered by new data presented in July 2026, highlighting Attruby's early and sustained direct kidney-protective effects in ATTR-CM, a key differentiator alongside its established cardiac benefits. Additionally, the failed CARDIO-TTRansform combination-therapy study reinforced the position of stabilizers like Attruby as the first-line treatment backbone.
2. Significant Advancement of Three Late-Stage Pipeline Programs into Regulatory Review. BridgeBio moved all three of its major pipeline assets into active regulatory review during fiscal Q2 2026, indicating substantial progress towards potential commercialization. The FDA accepted the New Drug Application (NDA) for BBP-418 for LGMD2I on May 27, 2026, granting it Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026. For encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1), the FDA accepted the NDA with Priority Review, setting a target date of May 8, 2027. Furthermore, an NDA for oral infigratinib for achondroplasia was submitted to the FDA, following positive Phase 3 PROPEL 3 results published in the New England Journal of Medicine in June 2026.
Show more
BridgeBio Pharma (BBIO) stock has gained about 20% since 4/30/2026 because of the following key factors:
1. Robust Commercial Performance of Attruby (acoramidis) Driven by Strong Revenue Growth and Differentiated Clinical Data. BridgeBio Pharma's flagship product, Attruby, demonstrated significant commercial success in fiscal Q2 2026 (ended June 30, 2026), with net product revenue reaching $222.4 million. This represents a substantial increase of $150.9 million year over year and more than $35 million sequentially. Management noted Attruby's 23% growth rate, outperforming the broader market's 19% increase. The commercial momentum was further bolstered by new data presented in July 2026, highlighting Attruby's early and sustained direct kidney-protective effects in ATTR-CM, a key differentiator alongside its established cardiac benefits. Additionally, the failed CARDIO-TTRansform combination-therapy study reinforced the position of stabilizers like Attruby as the first-line treatment backbone.
2. Significant Advancement of Three Late-Stage Pipeline Programs into Regulatory Review. BridgeBio moved all three of its major pipeline assets into active regulatory review during fiscal Q2 2026, indicating substantial progress towards potential commercialization. The FDA accepted the New Drug Application (NDA) for BBP-418 for LGMD2I on May 27, 2026, granting it Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026. For encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1), the FDA accepted the NDA with Priority Review, setting a target date of May 8, 2027. Furthermore, an NDA for oral infigratinib for achondroplasia was submitted to the FDA, following positive Phase 3 PROPEL 3 results published in the New England Journal of Medicine in June 2026.
Show more
Updated on 8/10/2026
BridgeBio Pharma (BBIO) stock has gained about 20% since 4/30/2026 because of the following key factors:
1. Robust Commercial Performance of Attruby (acoramidis) Driven by Strong Revenue Growth and Differentiated Clinical Data. BridgeBio Pharma's flagship product, Attruby, demonstrated significant commercial success in fiscal Q2 2026 (ended June 30, 2026), with net product revenue reaching $222.4 million. This represents a substantial increase of $150.9 million year over year and more than $35 million sequentially. Management noted Attruby's 23% growth rate, outperforming the broader market's 19% increase. The commercial momentum was further bolstered by new data presented in July 2026, highlighting Attruby's early and sustained direct kidney-protective effects in ATTR-CM, a key differentiator alongside its established cardiac benefits. Additionally, the failed CARDIO-TTRansform combination-therapy study reinforced the position of stabilizers like Attruby as the first-line treatment backbone.
2. Significant Advancement of Three Late-Stage Pipeline Programs into Regulatory Review. BridgeBio moved all three of its major pipeline assets into active regulatory review during fiscal Q2 2026, indicating substantial progress towards potential commercialization. The FDA accepted the New Drug Application (NDA) for BBP-418 for LGMD2I on May 27, 2026, granting it Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026. For encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1), the FDA accepted the NDA with Priority Review, setting a target date of May 8, 2027. Furthermore, an NDA for oral infigratinib for achondroplasia was submitted to the FDA, following positive Phase 3 PROPEL 3 results published in the New England Journal of Medicine in June 2026.
3. Strengthened Financial Position Through Strategic Financing. The company significantly enhanced its financial liquidity and runway with the closing of a $1 billion preferred equity financing on July 1, 2026. This financing boosted BridgeBio's cash, cash equivalents, and marketable securities to approximately $1.7 billion after the transaction, compared to $720.2 million as of June 30, 2026. This capital injection is expected to support the continued acceleration of Attruby and fund the potential launches of three additional medicines globally. The company also reported an improved operating loss for fiscal Q2 2026, narrowing to $107.1 million, a 20% improvement year over year.
4. Positive Analyst Sentiment and Upgraded Price Targets. Throughout the period, BridgeBio Pharma received favorable coverage from financial analysts. Several firms upgraded their price targets and maintained "Buy" or "Overweight" ratings on the stock. For instance, Morgan Stanley raised its price target from $94.00 to $98.00 in May 2026, and HC Wainwright increased its target from $110.00 to $120.00 in July 2026. Truist Financial also upped its target from $95.00 to $102.00. The consensus analyst rating for BridgeBio Pharma is "Moderate Buy" or "Strong Buy," with an average price target ranging from $97.33 to $105.26, suggesting further upside potential.
Show less
BridgeBio Pharma (BBIO) stock has gained about 20% since 4/30/2026 because of the following key factors:
1. Robust Commercial Performance of Attruby (acoramidis) Driven by Strong Revenue Growth and Differentiated Clinical Data. BridgeBio Pharma's flagship product, Attruby, demonstrated significant commercial success in fiscal Q2 2026 (ended June 30, 2026), with net product revenue reaching $222.4 million. This represents a substantial increase of $150.9 million year over year and more than $35 million sequentially. Management noted Attruby's 23% growth rate, outperforming the broader market's 19% increase. The commercial momentum was further bolstered by new data presented in July 2026, highlighting Attruby's early and sustained direct kidney-protective effects in ATTR-CM, a key differentiator alongside its established cardiac benefits. Additionally, the failed CARDIO-TTRansform combination-therapy study reinforced the position of stabilizers like Attruby as the first-line treatment backbone.
2. Significant Advancement of Three Late-Stage Pipeline Programs into Regulatory Review. BridgeBio moved all three of its major pipeline assets into active regulatory review during fiscal Q2 2026, indicating substantial progress towards potential commercialization. The FDA accepted the New Drug Application (NDA) for BBP-418 for LGMD2I on May 27, 2026, granting it Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026. For encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1), the FDA accepted the NDA with Priority Review, setting a target date of May 8, 2027. Furthermore, an NDA for oral infigratinib for achondroplasia was submitted to the FDA, following positive Phase 3 PROPEL 3 results published in the New England Journal of Medicine in June 2026.
3. Strengthened Financial Position Through Strategic Financing. The company significantly enhanced its financial liquidity and runway with the closing of a $1 billion preferred equity financing on July 1, 2026. This financing boosted BridgeBio's cash, cash equivalents, and marketable securities to approximately $1.7 billion after the transaction, compared to $720.2 million as of June 30, 2026. This capital injection is expected to support the continued acceleration of Attruby and fund the potential launches of three additional medicines globally. The company also reported an improved operating loss for fiscal Q2 2026, narrowing to $107.1 million, a 20% improvement year over year.
4. Positive Analyst Sentiment and Upgraded Price Targets. Throughout the period, BridgeBio Pharma received favorable coverage from financial analysts. Several firms upgraded their price targets and maintained "Buy" or "Overweight" ratings on the stock. For instance, Morgan Stanley raised its price target from $94.00 to $98.00 in May 2026, and HC Wainwright increased its target from $110.00 to $120.00 in July 2026. Truist Financial also upped its target from $95.00 to $102.00. The consensus analyst rating for BridgeBio Pharma is "Moderate Buy" or "Strong Buy," with an average price target ranging from $97.33 to $105.26, suggesting further upside potential.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 17.9% change in BBIO stock from 4/30/2026 to 8/12/2026 was primarily driven by a 42.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302026 | 8122026 | Change |
|---|---|---|---|
| Stock Price ($) | 71.11 | 83.84 | 17.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 502 | 713 | 42.0% |
| P/S Multiple | 27.4 | 23.0 | -16.0% |
| Shares Outstanding (Mil) | 194 | 196 | -1.1% |
| Cumulative Contribution | 17.9% |
Market Drivers
4/30/2026 to 8/12/2026| Return | Correlation | |
|---|---|---|
| BBIO | 17.9% | |
| Market (SPY) | 7.5% | 19.1% |
| Sector (XLV) | 15.4% | 24.3% |
Fundamental Drivers
The 8.5% change in BBIO stock from 1/31/2026 to 8/12/2026 was primarily driven by a 101.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 8122026 | Change |
|---|---|---|---|
| Stock Price ($) | 77.27 | 83.84 | 8.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 354 | 713 | 101.6% |
| P/S Multiple | 41.9 | 23.0 | -45.1% |
| Shares Outstanding (Mil) | 192 | 196 | -2.0% |
| Cumulative Contribution | 8.5% |
Market Drivers
1/31/2026 to 8/12/2026| Return | Correlation | |
|---|---|---|
| BBIO | 8.5% | |
| Market (SPY) | 11.9% | 31.8% |
| Sector (XLV) | 9.3% | 23.2% |
Fundamental Drivers
The 77.4% change in BBIO stock from 7/31/2025 to 8/12/2026 was primarily driven by a 459.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312025 | 8122026 | Change |
|---|---|---|---|
| Stock Price ($) | 47.27 | 83.84 | 77.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 127 | 713 | 459.6% |
| P/S Multiple | 70.5 | 23.0 | -67.4% |
| Shares Outstanding (Mil) | 190 | 196 | -2.9% |
| Cumulative Contribution | 77.4% |
Market Drivers
7/31/2025 to 8/12/2026| Return | Correlation | |
|---|---|---|
| BBIO | 77.4% | |
| Market (SPY) | 23.3% | 29.4% |
| Sector (XLV) | 30.8% | 22.6% |
Fundamental Drivers
The 139.5% change in BBIO stock from 7/31/2023 to 8/12/2026 was primarily driven by a 816.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312023 | 8122026 | Change |
|---|---|---|---|
| Stock Price ($) | 35.01 | 83.84 | 139.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 78 | 713 | 816.8% |
| P/S Multiple | 68.7 | 23.0 | -66.5% |
| Shares Outstanding (Mil) | 153 | 196 | -22.0% |
| Cumulative Contribution | 139.5% |
Market Drivers
7/31/2023 to 8/12/2026| Return | Correlation | |
|---|---|---|
| BBIO | 139.5% | |
| Market (SPY) | 74.7% | 35.7% |
| Sector (XLV) | 31.5% | 31.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BBIO Return | -77% | -54% | 430% | -32% | 179% | 9% | 18% |
| Peers Return | -14% | 31% | 5% | -3% | 23% | -11% | 26% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| BBIO Win Rate | 33% | 33% | 58% | 42% | 83% | 62% | |
| Peers Win Rate | 45% | 67% | 52% | 42% | 58% | 42% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| BBIO Max Drawdown | -84% | -70% | -31% | -45% | -20% | -20% | |
| Peers Max Drawdown | -39% | -26% | -32% | -32% | -40% | -33% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ALNY, BMRN, IONS, VRTX, SRPT. See BBIO Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/12/2026 (YTD)
How Low Can It Go
| Event | BBIO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -16.9% | -18.8% |
| % Gain to Breakeven | 20.4% | 23.1% |
| Time to Breakeven | 17 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -26.3% | -9.5% |
| % Gain to Breakeven | 35.6% | 10.5% |
| Time to Breakeven | 64 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.6% | -24.5% |
| % Gain to Breakeven | 229.4% | 32.4% |
| Time to Breakeven | 300 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -54.2% | -33.7% |
| % Gain to Breakeven | 118.3% | 50.9% |
| Time to Breakeven | 69 days | 140 days |
In The Past
BridgeBio Pharma's stock fell -16.9% during the 2025 US Tariff Shock. Such a loss loss requires a 20.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | BBIO | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -26.3% | -9.5% |
| % Gain to Breakeven | 35.6% | 10.5% |
| Time to Breakeven | 64 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.6% | -24.5% |
| % Gain to Breakeven | 229.4% | 32.4% |
| Time to Breakeven | 300 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -54.2% | -33.7% |
| % Gain to Breakeven | 118.3% | 50.9% |
| Time to Breakeven | 69 days | 140 days |
In The Past
BridgeBio Pharma's stock fell -16.9% during the 2025 US Tariff Shock. Such a loss loss requires a 20.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About BridgeBio Pharma (BBIO)
```html
BridgeBio Pharma, Inc. (BBIO) is a biotechnology company dedicated to the discovery, development, and delivery of innovative medicines for patients suffering from genetic diseases. The company maintains a robust and diverse pipeline of 30 development programs, encompassing product candidates from the earliest stages of discovery through advanced late-stage clinical trials.
The company's key product candidates target a range of serious genetic conditions. Among its most advanced programs are AG10 and BBP-265, small molecule stabilizers currently in Phase 3 clinical trials for transthyretin amyloidosis-cardiomyopathy (ATTR-CM). Other significant pipeline assets include BBP-831, a Phase 2 small molecule inhibitor for achondroplasia in pediatric patients; BBP-631, an AAV5 gene transfer product in Phase 2 for congenital adrenal hyperplasia (CAH); and Encaleret, a Phase 2 small molecule for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BridgeBio also has programs addressing hyperoxaluria, recurrent kidney stones, and broader initiatives in Mendelian, oncology, and gene therapy diseases.
BridgeBio Pharma primarily serves patient populations affected by rare and often severe genetic disorders. Its core market comprises individuals and families seeking transformative treatment options for conditions such as specific cardiomyopathies, skeletal disorders, endocrine imbalances, and metabolic diseases, which typically have high unmet medical needs. By concentrating on these genetic conditions, BridgeBio aims to provide vital therapies to patients who often lack adequate or effective treatment alternatives.
```AI Analysis | Feedback
1. BioMarin Pharmaceutical for a much broader range of rare genetic diseases.
2. Vertex Pharmaceuticals, focused on developing treatments for a diverse portfolio of genetic diseases.
AI Analysis | Feedback
- AG10 and BBP-265: These are small molecule stabilizers for transthyretin (TTR) amyloidosis-cardiomyopathy (ATTR-CM).
- BBP-831: This is a small molecule FGFR1-3 inhibitor designed to treat achondroplasia in pediatric patients.
- BBP-631: This is an AAV5 gene transfer product candidate for congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.
- Encaleret: This is a small molecule antagonist of the calcium sensing receptor (CaSR) for Autosomal Dominant Hypocalcemia Type 1 (ADH1).
- BBP-711: This product is developed to treat hyperoxaluria and prevent recurrent kidney stones.
AI Analysis | Feedback
BridgeBio Pharma, Inc. (BBIO) is a biopharmaceutical company focused on the discovery, development, and delivery of medicines for genetic diseases. As such, the company primarily sells its approved pharmaceutical products to other companies within the healthcare supply chain, rather than directly to individual patients.
The provided company description focuses on BridgeBio's extensive research and development pipeline, with many product candidates currently in clinical trials (Phase 2 and Phase 3). Therefore, specific major commercial customers for BridgeBio Pharma are not explicitly named in the background information.
However, upon commercialization of its medicines, BridgeBio's major customers would typically be:
- Pharmaceutical Wholesalers and Distributors: These companies purchase medicines in large volumes from manufacturers and distribute them to pharmacies, hospitals, and other healthcare providers nationwide. Major public companies in this sector include:
- Large Hospital Systems and Group Purchasing Organizations (GPOs): These entities purchase medicines directly for use within their networks of hospitals and clinics.
- Retail Pharmacy Chains and Pharmacy Benefit Managers (PBMs): Companies that manage prescription drug benefits and/or directly dispense medicines to patients. Examples of large public companies with significant presence in this area include:
AI Analysis | Feedback
- Leidos Biomedical Research, Inc. (Symbol: LDOS)
AI Analysis | Feedback
BridgeBio Pharma Inc. (BBIO) has a management team focused on discovering, developing, and delivering medicines for genetic diseases. The key members, including the CEO and CFO, bring a range of experience in the biotechnology and pharmaceutical sectors.
Here are some of the management team members:
**Neil Kumar, PhD**
Chief Executive Officer and Founder
Neil Kumar co-founded BridgeBio Pharma in 2015 and has served as its Chief Executive Officer and a director since April 2015. He also served as the Chief Executive Officer of Eidos Therapeutics, Inc., a clinical-stage biopharmaceutical company and a subsidiary of BridgeBio. Before founding BridgeBio, Dr. Kumar was a Principal at Third Rock Ventures, a venture capital firm, where he supported and managed portfolio companies and focused on new company formation and due diligence. During his time at Third Rock, he also served as the interim Vice President of Business Development and Operations for MyoKardia, Inc., a company later acquired by Bristol Myers Squibb. Prior to Third Rock, Dr. Kumar was an Associate Principal at McKinsey & Company, where he developed strategies for pharmaceutical and medical device companies. He holds BS and MS degrees in Chemical Engineering from Stanford University and a PhD in Chemical Engineering from the Massachusetts Institute of Technology.
**Thomas Trimarchi, PhD**
President and Chief Financial Officer
Dr. Thomas Trimarchi was appointed President and Chief Financial Officer (CFO) of BridgeBio Pharma on March 17, 2025. He previously served as the Principal Financial Officer and continues to lead the company's FP&A (Financial Planning & Analysis) and accounting operations. Dr. Trimarchi joined BridgeBio in 2018 as Chief Product Officer.
**Charles Homcy, MD**
Chairman of Pharmaceuticals
Dr. Charles Homcy has served as a member of BridgeBio's Board of Directors since November 2018 and as Chairman of Pharmaceuticals since February 2019. He has also held the role of Lead Director since February 2020. In 2010, Dr. Homcy joined Third Rock Ventures, a venture capital firm, where he currently serves on the Scientific Advisory Board.
**Uma Sinha, PhD**
Chief Scientific Officer
Uma Sinha is listed as the Chief Scientific Officer of BridgeBio Pharma, Inc.
**Richard Scheller, PhD**
Chairman of Research and Development
Dr. Richard Scheller is listed as the Chairman of Research and Development at BridgeBio Pharma, Inc. He also serves as a Director.
AI Analysis | Feedback
BridgeBio Pharma (BBIO) faces several key risks inherent to the biopharmaceutical industry, particularly given its stage of development and commercialization efforts.
Key Risks to BridgeBio Pharma (BBIO)
- High Cash Burn and Path to Profitability: BridgeBio Pharma continues to operate at a significant loss due to substantial research and development (R&D) and commercial launch costs. For example, in the third quarter of 2025, the company reported an operating loss of -$145.2 million against total revenue of $120.7 million. Analysts project a full-year 2025 net loss of approximately -$797.118 million. While the company is transitioning from a pure R&D entity to a commercial-stage enterprise with revenue from products like Attruby, it must quickly scale revenue to offset its high fixed costs and achieve profitability. The company's financial strength has been rated as poor, with concerns about debt levels and potential financial distress.
- Clinical Trial and Regulatory Success: The company's valuation is heavily dependent on the successful development and regulatory approval of its extensive pipeline of drug candidates. Any setbacks, delays, or negative results from late-stage clinical trials, such as those for encaleret, BBP-418, or infigratinib, could significantly impact the company's stock price and future prospects. The process of obtaining regulatory approval is fraught with uncertainties, posing a substantial risk to BridgeBio's business.
- Product Concentration and Intense Market Competition: BridgeBio Pharma currently exhibits a high concentration risk, with its initial commercial success largely driven by one drug, Attruby (acoramidis). Although Attruby has shown strong initial sales, it faces significant competition from established treatments like Pfizer's tafamidis (Vyndaqel/Vyndamax) and emerging RNA interference (RNAi) therapies. This competitive landscape could lead to slower market uptake, pricing pressures, or increased marketing expenditures. Similarly, other pipeline candidates, such as infigratinib for achondroplasia, will compete with existing approved therapies. The company needs its other late-stage assets to successfully launch and diversify its revenue streams to mitigate this concentration risk.
AI Analysis | Feedback
null
AI Analysis | Feedback
BridgeBio Pharma (BBIO) develops medicines for various genetic diseases, addressing several significant addressable markets:
- AG10 and BBP-265 (for Transthyretin Amyloidosis Cardiomyopathy, or ATTR-CM): The global transthyretin amyloidosis treatment market size was valued at USD 6.94 billion in 2024 and is projected to reach USD 20.35 billion by 2033, growing at a CAGR of 11.60% from 2025-2033. North America alone holds over 46.3% of this market in 2024. More specifically, the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) treatment market was estimated at USD 2.91 billion in 2025 and is expected to exhibit a CAGR of 31.1% to reach USD 19.37 billion by 2032.
- BBP-831 (for Achondroplasia): The global achondroplasia market was valued at approximately USD 157.75 million in 2024 and is projected to reach nearly USD 366.85 million by 2033, with a compound annual growth rate (CAGR) of around 9.9% during the forecast period. Other estimates for the global achondroplasia treatment market indicate it was valued at USD 235.92 million in 2024, expected to reach USD 3,856 million by 2033, growing at a CAGR of 36.40%.
- BBP-631 (for Congenital Adrenal Hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD): The global classic congenital adrenal hyperplasia market was valued at USD 284.31 million in 2024 and is expected to reach USD 563.19 million by 2032, growing at a CAGR of 8.92%. Another report estimates the global congenital adrenal hyperplasia treatment market to grow from USD 472 million in 2024 to USD 703 million by 2030, with a CAGR of 6.8%. The U.S. congenital adrenal hyperplasia treatment market is estimated at USD 188.8 million in 2024.
- Encaleret (for Autosomal Dominant Hypocalcemia Type 1, or ADH1): Autosomal Dominant Hypocalcemia Type 1 (ADH1) is a rare genetic form of hypoparathyroidism. The total hypoparathyroidism market size in the 7MM (United States, EU4 countries, United Kingdom, and Japan) was estimated to be approximately USD 370 million in 2023. The United States market alone accounted for approximately USD 200 million in 2023.
- BBP-711 (for Hyperoxaluria and Recurrent Kidney Stones):
- Hyperoxaluria: The global hyperoxaluria drug market size was valued at USD 19.43 million in 2024 and is expected to reach USD 32.40 million by 2032. For primary hyperoxaluria specifically, the global market reached US$ 168.96 million in 2023 and is expected to reach US$ 365.49 million by 2031. The global secondary hyperoxaluria drug market size was valued at USD 152.4 million in 2024 and is expected to reach USD 256.61 million by 2032.
- Recurrent Kidney Stones: The global kidney stone management market was valued at USD 2.57 billion in 2024 and is expected to reach USD 3.84 billion by 2032, growing at a CAGR of 5.14%. In the United States, the kidney stone management market was valued at USD 0.75 billion in 2024 and is expected to reach USD 1.11 billion by 2032.
AI Analysis | Feedback
Here are the 3-5 expected drivers of future revenue growth for BridgeBio Pharma (BBIO) over the next 2-3 years:
- Continued Commercial Growth of Attruby (acoramidis): Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is expected to be a significant revenue driver. BridgeBio reported strong commercial momentum for Attruby, with rising patient prescriptions and increasing market share in the U.S. The company also anticipates meaningful royalty revenue from its partner Bayer's European rollout of acoramidis.
- Launch of Infigratinib for Achondroplasia: BridgeBio has reported positive Phase 3 results for infigratinib in children with achondroplasia. The company plans to submit a New Drug Application (NDA) in the U.S. in the second half of 2026, with a potential launch targeted for the first half of 2027. Analysts project infigratinib could generate approximately $2 billion in peak sales.
- Launch of BBP-418 for LGMD2I/R9: Positive top-line Phase 3 results for BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) have been a key highlight. BridgeBio intends to submit an NDA to the FDA in the first half of 2026, with a U.S. launch anticipated in late 2026 to early 2027. This program is seen as a potential leader in its market, with analysts modeling approximately $1 billion in peak sales.
- Launch of Encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1): Encaleret, a small molecule antagonist of the calcium sensing receptor, has demonstrated positive top-line Phase 3 results for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BridgeBio anticipates launching encaleret in late 2026 or early 2027, with an estimated 3,000–4,000 identifiable patients in this market, and analysts modeling around $1 billion in peak sales.
AI Analysis | Feedback
Share Repurchases
- BridgeBio Pharma authorized a share repurchase program of up to $150 million in May 2021.
- In November 2021, the company repurchased $148.4 million in common stock under its 2021 Share Repurchase Program and an additional $50.0 million in conjunction with the issuance of 2029 convertible notes.
- The company repurchased 1,081,825 shares of its common stock for approximately $82.5 million in privately negotiated transactions in January 2026.
Share Issuance
- In March 2024, BridgeBio Pharma commenced an underwritten public offering of $250 million of shares of its common stock, with an option for underwriters to purchase up to an additional $37.5 million. This offering was priced on March 5, 2024, expecting gross proceeds of approximately $250.0 million.
Inbound Investments
- In August 2024, BridgeBio Pharma formed a joint venture, GondolaBio, with a consortium of investors contributing $300 million in financing. BridgeBio's initial ownership stake in GondolaBio is approximately 45%.
- BridgeBio Pharma issued $632.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2033 in a private offering in January 2026, generating approximately $619.3 million in net proceeds.
Outbound Investments
- In January 2021, BridgeBio Pharma completed the acquisition of all outstanding shares of Eidos Therapeutics, Inc. that it did not already own. Former Eidos stockholders received either 1.85 shares of BridgeBio common stock or $73.26 in cash for each share.
- BridgeBio Pharma contributed certain early-stage clinical and pre-clinical programs to the GondolaBio joint venture, which was formed in August 2024.
Capital Expenditures
- Capital expenditures for BridgeBio Pharma were $13 million in 2021.
- In 2023, the company reported capital expenditures of $1.31 million.
- BridgeBio Pharma's capital expenditures were $1.10 million in 2025.
Peer Outperformance in Biotechnology
BBIO has outperformed 84% of its 371 Biotechnology peers over 5Y. Biotechnology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that BBIO has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
70%
of 468 industry peers · 70.8% return
3Y
84%
of 414 industry peers · 169.8% return
5Y
84%
of 371 industry peers · 67.3% return
No Biotechnology peer with a comparable growth profile has beaten BBIO by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is BBIO's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 9.5% | 71.6% | 176.5% | CAH 405% · MCK 354% · SNYR 198% |
| Health Care Services | 20 | 24.8% | 33.4% | 10.1% | HIMS 258% · RDNT 152% · DGX 77% |
| Managed Health Care | 8 | 51.3% | -4.8% | 7.2% | OSCR 101% · HQY 54% · ELV 17% |
| Health Care Equipment | 51 | -2.7% | -10.6% | -17.3% | POCI 10275% · UFPT 417% · GKOS 281% |
| Health Care Facilities | 24 | 12.4% | -11.0% | -18.8% | THC 281% · NHC 239% · ENSG 120% |
| Health Care Supplies | 12 | 41.4% | -12.0% | -25.5% | LNTH 295% · HAE 49% · MMSI 38% |
| Pharmaceuticals | 64 | 4.2% | -3.0% | -40.0% | LQDA 2862% · INDV 1521% · ETON 841% |
| Health Care Technology | 21 | -15.2% | -55.4% | -72.3% | SPOK 135% · TALK 0% · HSTM -6% |
| Life Sciences Tools & Services | 111 | -4.3% | -34.4% | -72.6% | SNWV 2092% · ELMD 263% · MEDP 236% |
| Biotechnology ← | 372 | 12.1% | -29.2% | -77.3% | BRTX 106050% · DNTH 1643% · CELZ 1614% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 77.04 |
| Mkt Cap | 15.0 |
| Rev LTM | 2,690 |
| Op Inc LTM | 44 |
| FCF LTM | 400 |
| FCF 3Y Avg | 26 |
| CFO LTM | 484 |
| CFO 3Y Avg | 109 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.7% |
| Rev Chg 3Y Avg | 23.3% |
| Rev Chg Q | 16.2% |
| QoQ Delta Rev Chg LTM | 4.0% |
| Op Inc Chg LTM | -27.4% |
| Op Inc Chg 3Y Avg | 40.0% |
| Op Mgn LTM | 0.6% |
| Op Mgn 3Y Avg | 2.9% |
| QoQ Delta Op Mgn LTM | -1.7% |
| CFO/Rev LTM | 12.3% |
| CFO/Rev 3Y Avg | 0.1% |
| FCF/Rev LTM | 10.4% |
| FCF/Rev 3Y Avg | -3.7% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA216540 | ATTRUBY | acoramidis hydrochloride | tablet | 11222024 | 57.3% | 42.4% | 190.8% | 258.0% | 258.0% |
| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA216540 | ATTRUBY | acoramidis hydrochloride | tablet | 11222024 | 57.3% | 42.4% | 190.8% | 258.0% | 258.0% |
Price Behavior
Price Behavior
| Market Price | $83.84 | |
| Market Cap ($ Bil) | 16.3 | |
| First Trading Date | 06/27/2019 | |
| Distance from 52W High | -7.0% | |
| 50 Days | 200 Days | |
| DMA Price | $75.75 | $72.25 |
| DMA Trend | up | up |
| Distance from DMA | 10.7% | 16.0% |
| 3M | 1YR | |
| Volatility | 44.1% | 47.6% |
| Downside Capture | 16.67 | 108.17 |
| Upside Capture | 102.03 | 146.25 |
| Correlation (SPY) | 23.5% | 32.1% |
BBIO Betas & Captures as of 7/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.15 | 0.53 | 0.58 | 1.16 | 1.09 | 1.22 |
| Up Beta | 0.88 | 1.03 | 1.30 | 1.83 | 1.50 | 1.03 |
| Down Beta | 1.48 | 0.59 | 0.61 | 1.12 | 0.65 | 0.99 |
| Up Capture | 164% | 99% | 56% | 85% | 160% | 384% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 14 | 27 | 35 | 62 | 130 | 379 |
| Down Capture | 50% | -29% | 8% | 101% | 90% | 108% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 8 | 16 | 28 | 64 | 121 | 369 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BBIO | |
|---|---|---|---|---|
| BBIO | 74.2% | 47.5% | 1.31 | - |
| Sector ETF (XLV) | 31.1% | 15.5% | 1.54 | 21.8% |
| Equity (SPY) | 22.6% | 12.8% | 1.32 | 31.9% |
| Gold (GLD) | 31.4% | 28.4% | 0.95 | 13.0% |
| Commodities (DBC) | 37.9% | 20.1% | 1.48 | -10.2% |
| Real Estate (VNQ) | 14.3% | 13.8% | 0.73 | 10.6% |
| Bitcoin (BTCUSD) | -46.5% | 42.9% | -1.33 | 29.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BBIO | |
|---|---|---|---|---|
| BBIO | 9.3% | 85.9% | 0.53 | - |
| Sector ETF (XLV) | 6.4% | 15.0% | 0.24 | 21.2% |
| Equity (SPY) | 13.4% | 17.2% | 0.60 | 30.6% |
| Gold (GLD) | 19.0% | 18.6% | 0.83 | 4.7% |
| Commodities (DBC) | 9.8% | 19.6% | 0.39 | -2.3% |
| Real Estate (VNQ) | 2.2% | 18.9% | 0.01 | 26.6% |
| Bitcoin (BTCUSD) | 9.9% | 52.8% | 0.37 | 17.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BBIO | |
|---|---|---|---|---|
| BBIO | 11.6% | 83.1% | 0.59 | - |
| Sector ETF (XLV) | 10.2% | 16.6% | 0.50 | 24.0% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 31.7% |
| Gold (GLD) | 12.0% | 16.2% | 0.61 | 3.5% |
| Commodities (DBC) | 8.0% | 18.0% | 0.36 | 3.0% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 28.2% |
| Bitcoin (BTCUSD) | 60.9% | 66.1% | 1.01 | 17.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/13/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/10/2026 | -1.1% | ||
| 2/24/2026 | -2.6% | -5.5% | 4.8% |
| 10/29/2025 | -4.9% | -5.9% | 7.7% |
| 8/5/2025 | -8.9% | -0.2% | 5.3% |
| 4/29/2025 | 5.3% | 1.4% | -8.4% |
| 2/20/2025 | 1.4% | -7.8% | -6.6% |
| 11/12/2024 | -5.7% | -14.4% | 10.9% |
| 8/1/2024 | 0.9% | -7.8% | -5.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 11 | 13 |
| # Negative | 12 | 12 | 10 |
| Median Positive | 2.5% | 4.5% | 11.0% |
| Median Negative | -3.6% | -4.8% | -6.6% |
| Max Positive | 12.1% | 22.8% | 46.5% |
| Max Negative | -13.9% | -14.4% | -22.8% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/10/2026 | -1.1% | ||
| 2/24/2026 | -2.6% | -5.5% | 4.8% |
| 10/29/2025 | -4.9% | -5.9% | 7.7% |
| 8/5/2025 | -8.9% | -0.2% | 5.3% |
| 4/29/2025 | 5.3% | 1.4% | -8.4% |
| 2/20/2025 | 1.4% | -7.8% | -6.6% |
| 11/12/2024 | -5.7% | -14.4% | 10.9% |
| 8/1/2024 | 0.9% | -7.8% | -5.1% |
| 5/2/2024 | 2.6% | 2.5% | 3.6% |
| 2/22/2024 | -1.6% | 3.3% | -15.2% |
| 11/2/2023 | 1.0% | 10.3% | 16.1% |
| 8/3/2023 | 0.3% | -1.0% | -6.5% |
| 5/4/2023 | -6.2% | -4.0% | -1.0% |
| 2/23/2023 | -4.6% | -7.7% | 11.0% |
| 11/3/2022 | -0.2% | 3.1% | -7.0% |
| 8/4/2022 | 12.1% | 9.0% | 0.8% |
| 5/10/2022 | -13.9% | 22.8% | 23.8% |
| 2/24/2022 | 9.0% | 12.5% | 46.5% |
| 11/4/2021 | 2.9% | -1.4% | -22.8% |
| 8/13/2021 | -1.3% | -2.2% | -2.8% |
| 5/14/2021 | 0.9% | 7.9% | 16.4% |
| 2/26/2021 | 8.5% | -4.0% | -6.6% |
| 11/5/2020 | 2.4% | 2.4% | 30.4% |
| 8/11/2020 | -0.3% | 4.5% | 16.4% |
| SUMMARY STATS | |||
| # Positive | 12 | 11 | 13 |
| # Negative | 12 | 12 | 10 |
| Median Positive | 2.5% | 4.5% | 11.0% |
| Median Negative | -3.6% | -4.8% | -6.6% |
| Max Positive | 12.1% | 22.8% | 46.5% |
| Max Negative | -13.9% | -14.4% | -22.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/10/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/10/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 02/25/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/11/2020 | 10-Q |
| 03/31/2020 | 05/14/2020 | 10-Q |
| 12/31/2019 | 03/03/2020 | 10-K |
| 09/30/2019 | 11/08/2019 | 10-Q |
Recent Forward Guidance
Updated 8/11/2026Latest: Q2 2026 Earnings Reported 8/10/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2026 First participant dosed in Encaleret for chronic hypoparathyroidism | |||||||
| 2026 Phase 2 clinical trial update in hypochondroplasia | |||||||
Prior: Q4 2025 Earnings Reported 2/24/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Submit NDA to FDA for BBP-418 | |||||||
| 2026 Submit NDA to FDA for Encaleret | |||||||
| 2026 Submit NDA to FDA for Infigratinib | |||||||
| 2026 Initiate Phase 3 study for Encaleret | |||||||
| 2026 Phase 2 data for Infigratinib | |||||||
| 2027 Submit IND for Depleter | |||||||
Q3 2025 Earnings Reported 10/29/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 NDA Filing | |||||||
| 2026 Topline Results | Affirmed | Guidance: 0 for 2026 | |||||
Insider Activity
Updated 8/3/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Apuli, Maricel | Chief Accounting Officer | Direct | Sell | 8032026 | 80.06 | 2,000 | 160,120 | 10,199,724 | Form |
| 2 | Ellis, Andrea | Direct | Sell | 7132026 | 84.00 | 17,167 | 1,442,028 | 1,896,636 | Form | |
| 3 | Cook, Jennifer E | Direct | Sell | 7132026 | 88.54 | 148,589 | 13,156,008 | 742,227 | Form | |
| 4 | Cook, Jennifer E | Direct | Sell | 6242026 | 70.00 | 37,167 | 2,601,690 | 586,810 | Form | |
| 5 | Cook, Jennifer E | Direct | Sell | 6242026 | 68.57 | 2,196 | 150,580 | 574,822 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Apuli, Maricel | Chief Accounting Officer | Direct | Sell | 8032026 | 80.06 | 2,000 | 160,120 | 10,199,724 | Form |
| 2 | Ellis, Andrea | Direct | Sell | 7132026 | 84.00 | 17,167 | 1,442,028 | 1,896,636 | Form | |
| 3 | Cook, Jennifer E | Direct | Sell | 7132026 | 88.54 | 148,589 | 13,156,008 | 742,227 | Form | |
| 4 | Cook, Jennifer E | Direct | Sell | 6242026 | 70.00 | 37,167 | 2,601,690 | 586,810 | Form | |
| 5 | Cook, Jennifer E | Direct | Sell | 6242026 | 68.57 | 2,196 | 150,580 | 574,822 | Form | |
| 6 | Valantine, Hannah | Direct | Sell | 6242026 | 68.57 | 2,196 | 150,580 | 634,890 | Form | |
| 7 | Valantine, Hannah | Direct | Sell | 6242026 | 68.00 | 2,808 | 190,944 | 778,940 | Form | |
| 8 | Cook, Jennifer E | Direct | Sell | 6172026 | 66.62 | 90,240 | 6,012,157 | 438,986 | Form | |
| 9 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 6082026 | 67.88 | 20,000 | 1,357,540 | 35,003,208 | Form |
| 10 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 6082026 | 67.88 | 20,000 | 1,357,538 | 293,122,756 | Form |
| 11 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 6082026 | 67.46 | 20,000 | 1,349,106 | 36,134,873 | Form |
| 12 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 6082026 | 67.46 | 20,000 | 1,349,105 | 292,651,004 | Form |
| 13 | Kumar, Neil | Chief Executive Officer | Direct | Sell | 5262026 | 69.44 | 26,103 | 1,812,522 | 16,895,969 | Form |
| 14 | Trimarchi, Thomas | President and CFO | Direct | Sell | 5192026 | 65.08 | 13,651 | 888,419 | 23,376,664 | Form |
| 15 | Scott, Randal W | Direct | Sell | 5192026 | 67.15 | 10,000 | 671,456 | 778,150 | Form | |
| 16 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 5112026 | 66.91 | 20,000 | 1,338,151 | 37,179,585 | Form |
| 17 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 5112026 | 66.91 | 20,000 | 1,338,150 | 291,612,828 | Form |
| 18 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 5112026 | 67.90 | 20,000 | 1,357,972 | 39,088,277 | Form |
| 19 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 5112026 | 67.90 | 20,000 | 1,357,970 | 297,290,045 | Form |
| 20 | Apuli, Maricel | Chief Accounting Officer | Direct | Sell | 5042026 | 71.58 | 2,000 | 143,160 | 9,599,952 | Form |
| 21 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 4132026 | 74.60 | 20,000 | 1,492,096 | 44,441,035 | Form |
| 22 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 4132026 | 74.60 | 20,000 | 1,492,076 | 328,140,860 | Form |
| 23 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 4132026 | 74.62 | 20,000 | 1,492,304 | 45,939,534 | Form |
| 24 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 4132026 | 74.62 | 20,000 | 1,492,304 | 329,683,328 | Form |
| 25 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 3162026 | 68.79 | 20,000 | 1,375,890 | 43,731,709 | Form |
| 26 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 3162026 | 68.80 | 20,000 | 1,375,913 | 305,345,818 | Form |
| 27 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 3162026 | 68.73 | 20,000 | 1,374,605 | 45,065,447 | Form |
| 28 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 3162026 | 68.73 | 20,000 | 1,374,660 | 306,442,531 | Form |
| 29 | Valantine, Hannah | Direct | Sell | 3122026 | 72.00 | 8,671 | 624,312 | 537,480 | Form | |
| 30 | Ellis, Andrea | Direct | Sell | 3062026 | 64.87 | 64,921 | 4,211,302 | 1,205,833 | Form | |
| 31 | Valantine, Hannah | Direct | Sell | 3032026 | 67.41 | 25,484 | 1,717,781 | 503,188 | Form | |
| 32 | Apuli, Maricel | Chief Accounting Officer | Direct | Sell | 2272026 | 66.00 | 2,000 | 132,000 | 8,048,370 | Form |
| 33 | Kumar, Neil | Chief Executive Officer | Direct | Sell | 2232026 | 71.39 | 28,053 | 2,002,717 | 16,737,572 | Form |
| 34 | Apuli, Maricel | Chief Accounting Officer | Direct | Sell | 2182026 | 74.31 | 510 | 37,898 | 9,210,353 | Form |
| 35 | Trimarchi, Thomas | President and CFO | Direct | Sell | 2182026 | 74.72 | 13,600 | 1,016,147 | 25,148,520 | Form |
| 36 | Scott, Randal W | Direct | Sell | 2182026 | 75.46 | 10,000 | 754,557 | 874,456 | Form | |
| 37 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 2122026 | 71.78 | 20,000 | 1,435,543 | 48,498,809 | Form |
| 38 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 2122026 | 71.78 | 20,000 | 1,435,544 | 321,450,332 | Form |
| 39 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 2122026 | 71.94 | 20,000 | 1,438,822 | 50,048,431 | Form |
| 40 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 2122026 | 71.94 | 20,000 | 1,438,757 | 323,608,665 | Form |
| 41 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 1122026 | 77.11 | 20,000 | 1,542,198 | 55,186,484 | Form |
| 42 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 1122026 | 77.11 | 20,000 | 1,542,115 | 348,398,266 | Form |
| 43 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 1122026 | 73.97 | 20,000 | 1,479,422 | 54,419,507 | Form |
| 44 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 1122026 | 73.97 | 20,000 | 1,479,433 | 335,716,362 | Form |
| 45 | Kumar, Neil | Chief Executive Officer | Direct | Sell | 12162025 | 74.64 | 30,011 | 2,239,902 | 17,074,934 | Form |
| 46 | Apuli, Maricel | Chief Accounting Officer | Direct | Sell | 12102025 | 74.26 | 2,000 | 148,520 | 9,675,855 | Form |
| 47 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 12082025 | 73.31 | 20,000 | 1,466,276 | 55,402,198 | Form |
| 48 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 12082025 | 73.31 | 20,000 | 1,466,287 | 334,199,691 | Form |
| 49 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 12082025 | 74.40 | 20,000 | 1,487,958 | 57,709,424 | Form |
| 50 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 12082025 | 74.40 | 20,000 | 1,487,954 | 340,626,023 | Form |
| 51 | Kumar, Neil | Chief Executive Officer | Direct | Sell | 11242025 | 65.84 | 26,156 | 1,722,224 | 15,063,597 | Form |
| 52 | Lo, Andrew | Andrew W. Lo and Nancy N. Lo JTWROS | Sell | 11192025 | 65.69 | 55,000 | 3,613,069 | 3,322,907 | Form | |
| 53 | Lo, Andrew | Direct | Sell | 11192025 | 66.67 | 40,599 | 2,706,593 | 939,264 | Form | |
| 54 | Scott, Randal W | Direct | Sell | 11192025 | 66.65 | 10,000 | 666,465 | 772,366 | Form | |
| 55 | Trimarchi, Thomas | President and CFO | Direct | Sell | 11182025 | 66.46 | 16,934 | 1,125,404 | 25,442,221 | Form |
| 56 | Valantine, Hannah | Direct | Sell | 11142025 | 66.07 | 25,484 | 1,683,728 | 493,213 | Form | |
| 57 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 11102025 | 61.42 | 20,000 | 1,228,479 | 282,454,852 | Form |
| 58 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 11102025 | 61.43 | 20,000 | 1,228,515 | 48,875,615 | Form |
| 59 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 11102025 | 63.15 | 20,000 | 1,263,021 | 291,659,836 | Form |
| 60 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 11102025 | 63.15 | 20,000 | 1,263,095 | 51,514,460 | Form |
| 61 | Daniels, Ronald J | Direct | Sell | 11072025 | 63.72 | 61,031 | 3,888,999 | 1,082,695 | Form | |
| 62 | McCormick, Frank | the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 | Sell | 10312025 | 66.58 | 198,359 | 13,206,528 | 45,272,266 | Form | |
| 63 | McCormick, Frank | the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 | Sell | 10292025 | 65.00 | 1,641 | 106,665 | 57,091,970 | Form | |
| 64 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 10102025 | 54.80 | 20,000 | 1,096,046 | 254,197,564 | Form |
| 65 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 10102025 | 54.80 | 20,000 | 1,096,046 | 45,797,515 | Form |
| 66 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 10102025 | 54.78 | 20,000 | 1,095,674 | 255,207,037 | Form |
| 67 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 10102025 | 54.78 | 20,000 | 1,095,676 | 46,877,726 | Form |
| 68 | McCormick, Frank | Direct | Sell | 9082025 | 53.16 | 74,000 | 3,933,544 | 4,426,566 | Form | |
| 69 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 9082025 | 53.05 | 20,000 | 1,061,044 | 248,202,023 | Form |
| 70 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 9082025 | 53.05 | 20,000 | 1,061,003 | 46,455,269 | Form |
| 71 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 9082025 | 51.34 | 20,000 | 1,026,862 | 241,232,800 | Form |
| 72 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 9082025 | 51.35 | 20,000 | 1,026,926 | 45,990,161 | Form |
| 73 | Trimarchi, Thomas | President and CFO | Direct | Sell | 8222025 | 49.48 | 42,237 | 2,090,081 | 20,837,025 | Form |
| 74 | Kumar, Neil | Chief Executive Officer | Direct | Sell | 8222025 | 48.82 | 26,156 | 1,276,927 | 10,891,179 | Form |
| 75 | Trimarchi, Thomas | President and CFO | Direct | Sell | 8192025 | 50.23 | 17,353 | 871,722 | 23,274,632 | Form |
| 76 | Homcy, Charles J | Direct | Sell | 8122025 | 48.00 | 50,000 | 2,400,000 | 44,000,352 | Form | |
| 77 | Homcy, Charles J | Direct | Sell | 8122025 | 46.05 | 250,000 | 11,512,443 | 44,515,116 | Form | |
| 78 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 8112025 | 46.22 | 20,000 | 924,414 | 218,089,910 | Form |
| 79 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 8112025 | 46.22 | 20,000 | 924,414 | 42,323,645 | Form |
| 80 | Apuli, Maricel | Chief Accounting Officer | Direct | Sell | 8112025 | 45.44 | 1,000 | 45,440 | 6,446,073 | Form |
| 81 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | Sell | 8112025 | 45.45 | 20,000 | 909,061 | 215,376,794 | Form |
| 82 | Kumar, Neil | Chief Executive Officer | Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | Sell | 8112025 | 45.45 | 20,000 | 909,061 | 42,529,768 | Form |
| 83 | Ellis, Andrea | Direct | Sell | 8072025 | 49.00 | 17,167 | 841,183 | 910,861 | Form |
Investor Activity (13F)
Updated Aug 13, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Aisling Capital Management LP | $378.0 Mil | 79.4% | 13 | Hold | 13F |
| Laurion Capital Management LP | $115.3 Mil | 10.8% | 189 | Hold | 13F |
| Steelhead Partners LLC | $126.6 Mil | 9.1% | 24 | New | 13F |
| Catalio Capital Management, LP | $32.1 Mil | 6.7% | 41 | New | 13F |
| Frazier Life Sciences Management, L.P. | $256.1 Mil | 6.6% | 38 | Hold | 13F |
| First Turn Management, LLC | $51.7 Mil | 5.8% | 33 | ADD +16.8% | 13F |
| Boone Capital Management LLC | $17.0 Mil | 5.2% | 13 | ADD +23.7% | 13F |
| Silverback Asset Management LLC | $24.8 Mil | 4.9% | 45 | TRIM -18.2% | 13F |
| Eagle Health Investments LP | $19.8 Mil | 4.2% | 26 | Hold | 13F |
| Atle Fund Management AB | $11.9 Mil | 3.8% | 39 | TRIM -21.2% | 13F |
| Cormorant Asset Management, LP | $63.1 Mil | 3.2% | 46 | TRIM -29.2% | 13F |
| SC US (TTGP), LTD. | $138.2 Mil | 1.5% | 36 | Hold | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | As Of | Filing |
|---|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | $52.3 Mil | 1.4% | 29 | Exited | Dec 31, 2025 | 13F |
| Philosophy Capital Management LLC | $15.3 Mil | 1.8% | 34 | Exited | Dec 31, 2025 | 13F |
| Cormorant Asset Management, LP | $63.1 Mil | 3.2% | 46 | TRIM -29.2% | Mar 31, 2026 | 13F |
| Atle Fund Management AB | $11.9 Mil | 3.8% | 39 | TRIM -21.2% | Mar 31, 2026 | 13F |
| Silverback Asset Management LLC | $24.8 Mil | 4.9% | 45 | TRIM -18.2% | Mar 31, 2026 | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Aisling Capital Management LP | $378.0 Mil | 79.4% | 13 | Hold | 13F |
| Frazier Life Sciences Management, L.P. | $256.1 Mil | 6.6% | 38 | Hold | 13F |
| SC US (TTGP), LTD. | $138.2 Mil | 1.5% | 36 | Hold | 13F |
| Steelhead Partners LLC | $126.6 Mil | 9.1% | 24 | New | 13F |
| Laurion Capital Management LP | $115.3 Mil | 10.8% | 189 | Hold | 13F |
| Cormorant Asset Management, LP | $63.1 Mil | 3.2% | 46 | TRIM -29.2% | 13F |
| First Turn Management, LLC | $51.7 Mil | 5.8% | 33 | ADD +16.8% | 13F |
| Catalio Capital Management, LP | $32.1 Mil | 6.7% | 41 | New | 13F |
| Silverback Asset Management LLC | $24.8 Mil | 4.9% | 45 | TRIM -18.2% | 13F |
| Eagle Health Investments LP | $19.8 Mil | 4.2% | 26 | Hold | 13F |
| Boone Capital Management LLC | $17.0 Mil | 5.2% | 13 | ADD +23.7% | 13F |
| Atle Fund Management AB | $11.9 Mil | 3.8% | 39 | TRIM -21.2% | 13F |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 8/12/2026